Cart
sales@molnova.com
AZA1
CAS No. 1071098-42-4
AZA1( —— )
Catalog No. M35559 CAS No. 1071098-42-4
AZA1 (Rac1/Cdc42-IN-1) is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induced apoptosis of prostate cancer cells and inhibited cell proliferation, migration and invasion.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 147 | Get Quote |
|
| 5MG | 235 | Get Quote |
|
| 10MG | 377 | Get Quote |
|
| 25MG | 610 | Get Quote |
|
| 50MG | 869 | Get Quote |
|
| 100MG | 1152 | Get Quote |
|
| 500MG | 2313 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameAZA1
-
NoteResearch use only, not for human use.
-
Brief DescriptionAZA1 (Rac1/Cdc42-IN-1) is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induced apoptosis of prostate cancer cells and inhibited cell proliferation, migration and invasion.
-
DescriptionAZA1 is a potent dual inhibitor of Rac1 and Cdc42. AZA1 induces prostate cancer cells apoptosis and inhibits prostate cancer cells proliferation, migration and invasion.
-
In VitroAZA1 (Rac1/Cdc42-IN-1) (2-10 μM; 72 hours) blocks the proliferation of human prostate cancer cells 22Rv1 prostate cancer cells.AZA1 (2-10 μM; 24 hours) reduces phosphorylation of PAK1, AKT and BAD in EGF stimulated 22Rv1 prostate cancer cells.AZA1 (10 μM; 24 hours) blocks Rac1 and Cdc42-dependent cell cycle events in 22Rv1 prostate cancer cells.AZA1 blocks Rac1 and Cdc42-dependent migration of 22Rv1, DU 145 and PC-3 prostate cancer cells.AZA1 affects cell motility and actin rearrangement in prostate cancer cells by suppressing Rac1 and Cdc42 activity via PAK1/2 phosphorylation.Cell Proliferation Assay Cell Line:22Rv1 prostate cancer cells Concentration:2, 5, 10 μM Incubation Time:72 hours Result:Suppressed 22Rv1 prostate cancer cell proliferation in both unstimulated and EGF-stimulated cancer cells in a dose-dependent manner. Western Blot Analysis Cell Line:22Rv1 prostate cancer cells (EGF-stimulated)Concentration:2, 5, 10 μM Incubation Time:24 hours Result:Reduced phosphorylation of PAK1, AKT and BAD in EGF-stimulated 22Rv1 prostate cancer cells.
-
In VivoAZA1 (Rac1/Cdc42-IN-1) (100 μg; i.p.; daily for 2 weeks) is potent in suppressing human 22Rv1 xenograft growth in mice and improving survival.Animal Model:5 week-old athymic nu/nu (nude) mice (bearing 22Rv1 prostate cancer cell xenografts)Dosage:100 μg in 100 μl 30% DMSO Administration:I.p.; daily for 2 weeks Result:The suppressive effect of AZA1 on tumor growth was significant.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetRho
-
RecptorRho | Apoptosis | CDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1071098-42-4
-
Formula Weight368.43
-
Molecular FormulaC22H20N6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (135.71 mM; Ultrasonic )
-
SMILESCc1cc2cc(Nc3ccnc(Nc4ccc5[nH]c(C)cc5c4)n3)ccc2[nH]1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zins K, et al. A Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in mice. PLoS One. 2013;8(9):e74924. Published 2013 Sep 11.?
molnova catalog
related products
-
SAR407899
SAR407899 is Rho kinase inhibitor potently inhibits endothelin-1-induced constriction of renal resistance arteries.
-
EHop-016
EHop-016 is a specific Rac GTPase inhibitor with IC50 of 1.1 μM for Rac1 in MDA-MB-435 and MDA-MB-231 cells, equally potent inhibition for Rac3.
-
CCG-257081
CCG-257081 (MRTF/SRF-IN-1) is an inhibitor of cardiac myosin-related transcription factor and serum response factor (MRTF/SRF) that acts by inhibiting the Rho/MRTF/SRF pathway.CCG-257081 has shown efficacy in preventing bleomycin-induced fibrosis in several mouse models.
